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 Abstract: 
Cysteine proteases are implicated in a wide range of biological processes, which 
makes them an important factor in the pathogenesis of many diseases. 
Dysregulation of protease activity can lead to various diseases such as cancer, 
osteoporosis, neurological disorders and cardiovascular diseases. Furthermore, 
cysteine proteases have been proved to play a critical role in the life cycle of 
parasitic infections, an issue that grows every year due to increasing human 
migration. Therefore, cysteine proteases show great potential as targets for 
medicinal chemists.  
The following work aims to address this area of research through the synthesis of 
non-natural amino acid derived thiosulfonate warheads.  
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1 Introduction 
 
1.1  Motivation: 
 
Proteases are a large family of peptide-bond hydrolysing enzymes. They are present 
in all eukaryotic organisms and regulate a vast number of processes such as cell 
death, proliferation, migration and protein turnover.1 Dysregulation of these 
proteolytic enzymes can lead to the disruption of the biological processes they 
control. 
Among these enzymes, cysteine proteases have been recognised as causal agents 
in human pathologies.2 Furthermore, cathepsins have an essential role in the 
infectivity and life cycle of protozoa such as Plasmodium falciparum (Malaria), 
Trypanosoma brucei (African sleeping sickness) and Trypanosoma cruzi (Chagas 
disease), making them promising drug targets.3  
 
1.2 Active site and structure:  
 
Proteases hydrolyse peptide bonds and can be classified into five major classes: 
aspartic, threonine, serine, cysteine and metalloproteases.1 All papain-like cysteine 
proteases are composed of a left (-L) and a right (-R) domain. The L-domain 
contains three D-helices while the R-domain is a E-barrel closed at the bottom by a 
D-helix. The two domains form a cleft in the middle where the active site is situated.4 
Cysteine proteases are characterised by their highly conserved active site consisting 
of a cysteine, histidine and asparagine residue1 (figure 1). 
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Figure 1: Catalytic cycle of cysteine protease active site. 
 
Cys25 and His159 are thought to be catalytically active as a thiolate-imidazolium ion 
pair.1 The Asn175 forms a hydrogen bond to the His159 imidazole and orientates it in 
the optimum positions for various steps of the catalytic mechanism. The nucleophilic 
active site thiol can attack the carbonyl of the scissile bond (Figure 1, a) and form a 
tetrahedral intermediate (Figure 1, b) which collapses yielding a thioester (Figure 1, 
c). The thioester finally gets hydrolysed to yield the carboxylic acid and the active 
site nucleophilic thiol. 4 By contrast, other enzymes such as serine and threonine 
proteases have a nucleophilic oxygen in their active site. This key distinction can be 
used when designing a specific inhibitor that can differentiate between enzyme 
classes and interact only with the active site thiol of cysteine proteases.  
According to the nomenclature of Schecter and Berger5 there are seven subsites in 
the binding area of cysteine proteases. Four on the acyl side (S4, S3, S2, S1) and 
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three (S1’, S2’, S3’) on the amino side of the scissile bond (Figure 2).  The S2, S1 
and S1’ subsites are the three well defined sites where residues can interact with the 
enzyme by both their main and side chain. It is worth noting that the S2 binding site 
is the largest and most defined in papain cysteine proteases and thus the interaction 
between the S2 site and the complementary P2 residue is key in determining 
inhibitor specificity.6  
 
Figure 2: Representation of enzyme-substrate complex and the seven binding subsites.  
 
Cathepsins are proteases found in all animals and most other organisms. Most of the 
members of this group become activated at low pH and their activity lies almost 
entirely within the acidic environment of the lysosomes.  There are 11 cysteine 
cathepsins expressed in the human genome1. Most cathepsins have structures 
composed of two domains (left and right domain) and the active site cleft in the 
middle. Depending where they cleave their substrates, cathepsins can be classified 
as exopeptidases (Cathepsin B, C and X) or endopeptidases (Cathepsin L, F and 
K).6 A typical feature cathepsin B-like cysteine proteases is the existence of an 
occluding loop between conserved Pro-Tyr103 motif and Cys128. This loop contains 
two histidine residues (His110 and His111) which anchor the C-terminal carboxyl group 
of peptide and protein substrates and are responsible for the dipeptidyl 
carboxypeptidase activity of the enzyme (removes C-terminal dipeptides)7. 
Cathepsin L has an endopeptidase activity and will selectively cleave peptides with 
aromatic residues in the P2 position and hydrophobic residues in the P3 position.8 
These differences can be exploited to design a more specific inhibitor that can target 
individual cysteine proteases.  
 
1.3  Cysteine proteases in cancer:  
 
The broad range of the biological processes that cathepsins are involved in indicates 
their importance within the organism. Aberrant cathepsin activity has been shown to 
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contribute to many diseases such as: osteoporosis, arthritis, obesity, cystic fibrosis, 
many types of cancer and parasitic pathogenesis.9  
In many cancer types, increased levels of cathepsins correlate to increased 
malignancy. Dysregulation of cysteine protease activity is crucial for tumourgenesis. 
Cathepsins recycle proteins for cancer cell survival and proliferation, and they modify 
tumour microenvironment which leads to invasion and disease progression. They 
also contribute to activation of growth factors, immune system regulation and 
metastasis. Therefore, cysteine cathepsins represent an important class of proteins 
that facilitate cancer progression.10  
The attempt of cancer treatment via protease inhibition was done via matrix 
metalloproteases (MMPs) 11. However, MMPs failed in clinical trials which led to the 
termination of their use. These molecules reached phase III in clinical trials but were 
terminated due to their activity against both pro and anti-tumorigenic proteases. 
Furthermore, they proved to be effective only against early stages of cancer and had 
considerable toxicity in some patients. A critical advantage that cystine protease 
inhibitors have over MMPIs is that in addition to increased expression, aberrant 
cathepsins also change their position from being in the lysosome to moving onto the 
cell surface. The tumour environment is acidic so the cathepsins can work outside 
the cell. This may allow differential targeting of tumour-specific cathepsins through 
inhibitor design towards the tumour microenvironment. For example, inhibitors which 
are poorly cell permeable may prove advantageous as they would leave cathepsins 
that function normally untouched.11 
Some cathepsins have been shown to have a role in acquired radiation and 
chemotherapy resistance and their inhibition has improved the outcome of such 
treatments.9 Furthermore, whist cathepsins can exhibit tumour-promoting activity, 
there are also cysteine cathepsins which have shown tumour supressing activity, 
highlighting the need for higher selectivity. 
 
 
1.4  Cysteine proteases in parasitic infections: 
 
Cysteine proteases are fundamental to the metabolism of many tropical parasites 
and cysteine protease inhibitors have been shown to stop parasitic infections both in 
cell cultures and animal models.12 
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Chagas disease is the leading cause of heart disease in South America, causing 
over 15.000 deaths each year and it is caused by the protozoan parasite 
Trypanosoma cruzi. 13 
 
 
Figure 3: Life cycle of Chagas disease (https://www.cdc.gov/parasites/chagas/biology.html). 
 
The cysteine protease Cruzain is essential for T. cruzi as it is involved in all stages of 
the parasite’s life cycle (Figure 3) – infection, growth, nutrition and immune system 
evasion.14 An advantage of cysteine protease inhibitors is that by selectively 
targeting Cruzain, the infection can be stopped at any stage during its life cycle, not 
only when its most infective. The World Health Organisation (WHO) recommended 
two drugs for the treatment of the disease: nifurtimox and benznidazole (Figure 4). 
However, they are less effective once the infection reaches the chronic phase and 
display severe side effects.15 
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Figure 4: Structures of Benznidazole and Nifurtimox. 
 
K11777 (Figure 5) is a vinyl sulfone inhibitor that has shown good efficacy in mouse 
and dog models, low toxicity, and selectivity towards Cruzain over mammalian 
cysteine proteases.16 It is also important to note that K11777 achieved the removal 
of both parasite adult worms and drastically reduced the quantity of eggs present in 
the liver and spleen, proving that a protease inhibitor can target the parasitic 
infection regardless of the stage in its lifecycle.2  A factor contributing to K11777’s 
high efficacy is that Cruzain has a strong preference for large hydrophobic residues 
in the P2 position, as this determines specificity by interacting with the S2 binding 
pocket of the cysteine protease family. Furthermore, although the P3 position is of 
little importance to binding, modifying it influences a number of properties including 
hepatotoxicity, lipophilicity and pharmacokinetics. It was determined that including 
the N-methylpiperazine in the P3 position would increase the bioavailability by 
increasing absorption in the small intestine. 
 
 
 
Figure 5: Structure of K11777 
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1.5  Current inhibitors:  
 
 
 
Figure 6: Structures of currently used inhibitors: nitrile (AAE-581), epoxysuccinyl (E-64, JPM-OEt), 
vinyl sulfones (WRR-483). 
 
Several small molecules have been designed to selectively target and inhibit the 
activity of cysteine proteases.  The main classes of inhibitors that have been tested 
on animal models and in clinical trials are nitriles, vinyl sulfones and epoxysuccinyl-
derived molecules.1 These can be either broad spectrum inhibitors or specific for 
particular members of the cysteine protease family. Many of these inhibitors are 
composed of a “backbone” that confers specificity for the required cysteine protease 
type and an electrophilic warhead that can react with the active site thiol. Figure 6 
shows some of the inhibitors that are most widely used. Although most of these 
inhibitors show promising activity in vitro, when tested in vivo they were not as 
effective. For example, Cathepsin K inhibitors such as AAE-581 accumulate in the 
lysosome due to their lipophilic profile and end up inhibiting off-target enzymes such 
as Cathepsin S.10 
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E-64 is an epoxysuccinyl based inhibitor and it was extracted from Aspergillus 
japonicus.10 E-64 is an irreversible, broad spectrum inhibitor, which was tested on 
Japanese adults with muscular dystrophy, but the drug was stopped at phase III due 
to off-target activity. The studies showed that E-64 had good efficacy but it would 
also covalently bind other proteases that were closely related to the cathepsin 
family.9 Further modifications to the molecule have yielded more specific and less 
toxic inhibitors such as JPM-OEt but they are yet to be tested in clinical trials.17 The 
vinyl sulfone K11777 has shown remarkable efficacy and low toxicity in animal 
models and is currently undergoing clinical trials. WRR-483 is a derivative of K11777 
in which the P2 residue was changed from a phenylalanine to an arginine in the 
hope of achieving higher selectivity. Although the attempt to make the inhibitor more 
selective proved successful, the overall efficacy was decreased by putting an 
arginine in the P2 position. Considering its potential, low toxicity and high potency, 
we have chosen to use vinyl sulfone inhibitor K11777 as a foundation for the design 
of the thiosulfonate inhibitor.  
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1.6  Thiosulfonates: 
 
 
 
  
 
Figure 7: Mechanism of K11777 cysteine protease inhibitor compared to proposed thiosulfonate 
mechanism. 
 
In this work, thiosulfonates will be explored as novel warheads for use as cysteine 
protease inhibitors. Methylmethanethiosulfonate (MMTS) is the simplest 
thiosulfonate and it is a cysteine protease inhibitor used to measure protease activity 
in biological assays. MMTS has also displayed anti-cancer and anti-bacterial 
activity.18 A very important aspect of thiosulfonates is their selective interactions with 
protein thiols. This can be of great value in the synthesis of specific inhibitors. 
Therefore, we have chosen to include a thiosulfonate warhead in our inhibitors 
(Figure 7) in order to specifically target cysteine proteases over other classes of 
enzymes that are present in the body. Furthermore, previous work in the Liskamp 
group (not published) has shown that replacing the aromatic moiety in the P1’ 
position for an aliphatic moiety in thiosulfonates enhanced the potency of the 
10 
 
inhibitors. This was thought to be through down-regulating the reactivity of the 
warhead. Taking this together with the backbone of K11777, a cysteine protease 
inhibitor that made it to late stage clinical trials shows potential for a successful line 
of inhibitors. K11777 will provide an ideal reference compound allowing conclusion to 
be drawn solely on the effect of the warhead and not backbone alterations. 
The rationale behind the backbone design is that having N-methylpiperazine in the 
P3 position increases the inhibitor’s assimilation in the small intestine, while the 
homophenylalanine side chain takes advantage of the P2 specificity of cathepsin-L 
like cysteine proteases, thus conferring the inhibitor specificity towards a certain 
member within the protease family.  
 
Figure 8: Thiosulfonate forming hydrogen bonds to His159 (shown in red) of the cysteine protease 
active site.  
 
The novel thiosulfonate warheads build on this specificity as other enzymes such as 
serine and threonine proteases have a nucleophilic oxygen in their active site. These 
oxygen-centred nucleophiles are hard nucleophilic centres while the active site thiol 
of cysteine proteases offers a soft nucleophile. Thiosulfonates aim to exploit this 
difference as the bivalent sulphur of the thiosulfonate moiety offers a soft 
electrophile, thus increasing the selectivity towards the soft sulphur-centred 
nucleophile of cysteine proteases. Furthermore, modelling studies have shown that 
the hexavalent sulphur forms favourable interactions (hydrogen bonds) with His159 of 
the cysteine protease active site (Figure 8).  
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Previous work within the Liskamp group (unpublished) has shown that improving the 
stability of the thiosulfonates by down-regulating their reactivity has previously been 
shown to increase the potency. Other methods to expand on this observation will 
also be explored such as further substitution of the thiosulfonate warhead on the 
carbon adjacent to the bivalent sulphur. The strategy is expected to decrease the 
rate of a nucleophilic attack on the bivalent sulphur, thus improving stability, which is 
expected to translate into improved potency as previous inhibitors could be degraded 
before reaching the target enzyme.   
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2 Results: 
2.1 Exploring efficient thiosulfonate synthesis methods: 
 
The main aim of the project was to deliver an efficient synthesis towards the 
warhead component which would be coupled to the inhibitor backbone later. The 
synthesis for this component can be seen in Scheme 1.  
 
 
 
Scheme 1: Warhead synthesis: a) Boc2O, NaOH, THF, 97%; b) MeI, K2CO3, DMF, 95%; c) NaBH4, 
LiCl, EtOH, THF, 70%; d) MsCl, NEt3, DCM, 75%; e) Cs2CO3, AcSH, DMF, 38%; f) LiAlH4, THF, -
78ºC, 94%; g) C16H11BrSO2, DCM, 0ºC, 20%.  
 
This method offers a quick and efficient route to the synthesis of thiosulfonate 
warheads that can then be incorporated in the main inhibitor via peptide coupling. By 
analogy to K11777, it was decided that the synthesis would be started from 
homophenylalanine which could be derivatised to obtain the thiosulfonate warhead 
along with the P1 residue. Synthesis was started from commercially available 
homophenylalanine 1 which was Boc protected to obtain compound 2. The 
carboxylic acid was then converted to a methyl ester by alkylation under basic 
conditions to avoid Boc deprotection. Methyl ester 3 was then reduced to an alcohol. 
Following this, a functional group transformation converting alcohol 4 to a good 
leaving group was required, hence mesylation to 5 was chosen. The mesylate was 
required for a subsequent conversion to thioacetate 6 via an SN2 reaction that would 
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introduce the sulphur functionality. At this stage, the thioacetate needed to be 
converted to a thiol. Initially, hydrolysis using EtOH, KOH and 2% water was 
attempted. This method yielded disulphide 9 as the major by-product (scheme 2) due 
to oxidation of the free thiol by atmospheric oxygen. Although all efforts were made 
to exclude oxygen from the reaction, it was determined that the basic conditions 
were accelerating this unwanted side reaction. Thus, as avoiding these conditions 
may improve the yield, reduction utilising LiAlH4 was used. 
 
 
 
Scheme 2: Optimising thioacetate to thiol conversion to avoid undesired disulphide formation: a) 
EtOH, KOH, 2% water, 20% 7 and 80% 9. b) unwanted disulphide bond formation. 
 
The reduction using LiAlH4 was successful with a 94% yield and was kept in the final 
synthetic route. The final step (scheme 1, g) is crucial to the synthesis as it forms the 
aliphatic thiosulfonate. Previously, sulfonyl chlorides were explored within the 
Liskamp group for this reaction, but it was found that this formed the symmetrical 
disulphide 12 as the major product, as shown in Scheme 3.   
 
 
 
Scheme 3: Thiosulfonate formation using sulfonyl chlorides; a) DCM, DiPEA, 0qC, b) unwanted side 
reaction with second equivalent of thiol. 
 
It was hypothesised that this unwanted side-reaction is happening because the rate 
of formation of disulphide (step b, k2) is faster than the rate of thiosulfonate formation 
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(step a, k1). Thus, sulfonyl bromides were introduced to try and increase the rate of 
k1 relative to k2, and favouring formation of thiosulfonate over disulphide. The use of 
sulfonyl bromides yielded a higher conversion to thiosulfonate with trace amount of 
disulphide by-product. With a successful, high yielding synthesis towards aliphatic 
thiosulfonates, we envisioned the final step (scheme 1, g) could be optimised to a 
one pot reaction allowing rapid expansion of the substrate scope.  
Initially, it was hypothesised that the conditions in scheme 4 would be possible for 
sulfonyl bromide formation in situ and the introduction of the thiol in a one pot 
manner. If this proved to be successful, then substrate scope could be rapidly 
expanded in a one pot manner by varying the thiol starting material to generate a 
range of sulfonyl bromides in situ. 
 
 
Scheme 4: One pot cyclohexane thiosulfonate formation; a) NBS, 2M-HBr, MeCN; b) addition of 
RSH. 
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The one-pot method was attempted with the conditions shown in scheme 4. 
However, this yielded only trace amount of thiosulfonate and symmetrical disulphide 
as the major product. It was thought that this was due to the sulfonyl bromide being 
formed too slowly or not at all and so reaction conditions were screened as shown in 
table 1. Using conditions presented in entry 1, symmetrical disulphide of the starting 
thiol was observed as the major product. At first, this was thought to happen due to 
the fact that the sulfonyl bromide is not being formed prior to the addition of thiol. 
 
 
 
 
 
Table 1: Scanning conditions for sulfonyl halide. 
 
The number of equivalents of NBS was increased in order to ensure that the sulfonyl 
bromide was properly formed before the addition of the thiol (table 1, entry 2). As this 
was met with limited success, it was thought that the thiol was being oxidised by the 
extra equivalents of oxidant added. Hence, as presented in entry 3, we eliminated 
the acid. This was done in consideration to the fact that the NBS supplies 
oxidant/bromide and H2O is the oxygen source. Hence, it was assumed there is no 
need for acid in the mechanism. However, this caused the sulfonyl halide to not be 
formed at all, implying that the acid was required for successful bromination and 
sulfonyl bromide formation.  
As multiple mechanisms can be drawn to produce the sulfonyl bromide under the 
previously mentioned conditions, reaction control through regulation of number of 
Entry Reaction conditions Sulfonyl halide Yield (%) 
1 NBS (3 eq.), 2M-HBr (2% vol.), MeCN 25 - 30 
2 NBS (4 eq.), 2M-HBr (2% vol.), MeCN 15 - 20 
3 NBS (4 eq.), MeCN: H2O (50:50) - 
4 Oxone (2.5 eq.), KBr (1 eq.), MeCN trace 
5 Oxone (3.5 eq.), KBr (1 eq.), MeCN 15 - 20 
6 Oxone (1.5 eq.), KBr (0.5 eq.), MeCN trace 
7 Oxone (2.5 eq.), KBr (1 eq.), MeCN, DiPEA - 
8 Oxone (2.5 eq.), KI (1 eq.), MeCN              - 
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equivalents was difficult to achieve. As excess oxidant could instantly oxidise the 
second thiol upon addition, other oxidants with a more specific mechanism were 
considered.  
A literature review found Oxone20 (KHSO5) as an oxidant which may be suitable for 
the transformation of thiols to sulfonyl bromides. Upon examination of the 
mechanism presented in scheme 4, it can be seen that the advantage of this method 
is that the outcome could be, in theory, easily controlled by varying the amount of 
oxidant/reagents. Furthermore, the desired sulfonyl halide is produced while the 
symmetrical disulphide 18 is being consumed as part of this cycle. Thus, even if the 
unwanted side-reaction produces symmetrical disulphide (as in Scheme 3, b), this 
will be consumed with the addition of Oxone and KX. So, by carefully controlling the 
equivalents of oxidant and acid added, we can eliminate undesired disulphide by-
products formed through oxidation of the second thiol by excess oxidant. Oxone 
reacts with the KX to produce hypohalous acid (HOX). Next, the hypohalous acid 
reacts with the unreacted thiol to produce a sulfinyl halide 17 which then reacts with 
another equivalent of thiol and is converted to disulphide 18. The disulphide reacts 
with one equivalent of hypohalous acid to give compound 19 which reacts with 
another equivalent of HOX to form 20. Compound 20 then rearranges to the 
symmetrical thiosulfonate 21. This can then react with a second equivalent of KX 
and form the sulfonyl halide 22 which we need for our one pot procedure.  As can be 
seen from the mechanism, for every two equivalents of Oxone and one equivalent of 
potassium halide added to the reaction, we get one equivalent of HOX. Tuning the 
number of equivalents of oxidant added, we can ensure that upon addition, the 
second equivalent of thiol will not be instantly oxidised to the symmetrical disulphide 
upon addition. Work started with addition of the equivalents used cited by 
Madabhushi et al (entry 4, table 1) but this only yielded trace sulfonyl halide. The 
next logical step was to add more equivalents of Oxone (entry 5) and acid so that the 
reaction goes all the way to compound 22. This gave a 15-20% yield for sulfonyl 
halide formation in separate steps but only trace amount of product when attempted 
in a one pot reaction. 
Considering that the quantity of KX determine the amount of HOX going into the 
reaction, the amount of potassium halide used to test how this would influence the 
outcome (entry 6). Only trace amounts of sulfonyl halide were observed meaning, in 
this case, at least one equivalent of KX is required to form the sulfonyl halide. 
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Next, DiPEA was added in an attempt to increase the nucleophilicity of the second 
thiol, and thus increase the reaction rate of thiosulfonate formation and avoid thiol 
oxidation due to excess oxidant. This reaction only yielded trace amounts of sulfonyl 
bromide. Next, the use of iodide for the formation of the thiosulfonate was attempted 
in order to increase the leaving group ability hence reaction rate in an effort to 
increase the formation of thiosulfonate with respect to competing side reactions. As 
presented in entry 8, when Oxone and potassium iodide were used, neither sulfonyl 
iodide or starting material were observed. Finally, since most of the changes proved 
to be unsuccessful or hard to trace/follow, the initial conditions were kept, and the 
reaction was done in separate steps.  
 
 
 
Scheme 5: Mechanism of sulfone formation upon oxidation with Oxone. 
 
Although the route provided in scheme 1 was successful for cyclohexane thiol 
warhead, when it was used to prepare the cyclopentane thiol, symmetrical disulphide 
was observed as a main product and only trace amounts of the desired warhead was 
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obtained.  The reasons for this observation are not yet clear as the chemistry of the 
cyclopentane and cyclohexane systems was not thought to differ drastically. 
Cuevas et al21 describe a method of making sulfonyl halides by using iPrOH as a 
source of oxygen. However, the use of iPrOH makes filtering of the product 
inefficient and other methods of purification proved unsuccessful and no clear 
product could be identified. 
Moving forward, it was decided to try and obtain the thiosulfonate by using a 
sulfinate salt with the aim of applying this to a wider substrate scope, as the sulfonyl 
bromides were only efficient when generating the cyclohexane derivative. The 
advantage of this method is the increased stability of the sulfinate salt over the 
sulfonyl bromide, making it potentially easier to work it. Furthermore, the starting 
material is now the symmetrical disulphide rather than the thiol, meaning the strict 
anaerobic conditions are not required to ensure the thiol is not oxidised to an 
unwanted disulphide. The reduction of sulfonyl chloride with Na2CO3 and NaHCO3 
was carried out at 50ºC and the mixture was allowed to stir for 30 mins. Next, 
sulfonyl chloride was added followed by the disulphide. The reaction was allowed to 
stir overnight, and an 1H NMR spectrum of the product was obtained but no 
thiosulfonate was observed.  
 
 
Scheme 6: Sulfinate salt method: a) NCS, 2M-HCl, MeCN; b) Na2SO3, NaHCO3, 50ºC 
SH SO
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2.2 Methyl warhead design:  
 
Based on the arguments above, alternative methods to modify the thiosulfonate 
warhead were pursued. Rather than expanding the substrate scope at the primed 
side, focus now turned towards controlling reactivity by steric control. Previous work 
within the Liskamp group (not published) found that the thiosulfonate warhead is 
highly tuneable and aliphatic analogues are the most promising due to their 
decreased reactivity profiles. To push this concept further it was suggested that 
introduction of a methyl substituted in the position adjacent to the bivalent sulphur 
might decrease the rate of nucleophilic attack, and thus increasing the stability of the 
inhibitor. The increase in stability is anticipated to be met with an increased in 
potency as this trend has been observed in previous work done within the Liskamp 
group (not published).  
The synthesis used D-threonine as a starting point. This amino acid is commercially 
available, cheap and the easy functionalisation of the carboxylic acid opens up a 
wide range of possibilities in terms of non-natural amino acids for future warhead 
design. In this instance, the final compound was desired to have a 
homophenylalanine side chain. To achieve this, the carboxylic acid was converted 
into a methyl ester (step a, scheme 7). Next, the amine and alcohol functionalities 
were protected using Boc and TBDMS respectively, yielding compound 27. 
Reduction of the methyl ester directly to an aldehyde using DIBAL-H in a controlled 
manner was attempted. This reagent had no effect and only starting material could 
be observed even with extra equivalents of DIBAL-H. Consequently, it was decided 
to reduce the methyl ester to a primary alcohol 28 using LiAlH4 and then oxidise to 
aldehyde 29 using Swern conditions. 
The resulting aldehyde was checked by use of LCMS and TLC and the purity was 
sufficient for addition in the subsequent Wittig reaction. Due to time constraints, the 
synthesis will be carried further by a MSci student, but the subsequent steps will be 
briefly discussed.  
With compound 30 in hand, the next step will be the hydrogenation of the alkene to 
an alkane, providing the key building block of homophenylalanine with a single 
methyl substituent next to the alcohol functionality. This will be followed by TBAF 
removal of the TBDMS protecting group to yield the secondary alcohol 31. Next, the 
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mesylate functionality will be installed to provide a good leaving group for the next 
step of the synthesis. Following this, the thioacetate moiety will be introduced and 
reduced to give the corresponding thiol 34, which can be coupled to a sulfonyl halide 
to form the thiosulfonate warhead 35. 
 
Scheme 7: Synthesis route for methylated warhead: a) Thionyl chloride, MeOH, 70qC, 2h, 95%; b) 
Boc2O, DiPEA, DMF, 95%; c) TBDMS-Cl, Imidazole, DMF, 3h, 25%; d) LiAlH4, dry THF, -78qC, 95%; 
e) Oxalyl chloride, DMSO, Triethylamine, -78qC, dry THF; f) Triphenyl phosphine ylide, dry DCM, 
product formation observed by LCMS; g) H2, Pd/C; h)MsCl, NEt3, DCM; i) Cs2CO3, AcSH, DMF; k) 
LiAlH4, THF l) Sulfonyl bromide, DCM.  
 
2.3  Backbone synthesis: 
 
Finally, the backbone was synthesised alongside the warhead fragment in 
anticipation of the final compound coupling.  The backbone component was kept 
identical to K11777 in order to be able to draw direct comparisons between the 
newly synthesised inhibitors and the reference vinyl sulfone inhibitor, observing only 
the effect of the warhead on the overall stability and potency of the molecule. The 
backbone was synthesised using the route presented in scheme 8. The synthesis 
was started from commercially available Boc-Phenylalanine and the carboxylic acid 
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was converted into benzyl ester 37. Next, the Boc protecting group was removed so 
that the N-methylpiperazine group could be installed. This was done in two 
subsequent steps, first using Triphosgene and NaHCO3 to generate isocyanate, 
followed by addition of N-methylpiperazine. Finally, the benzyl ester was removed 
using hydrogen with a palladium/carbon catalyst and compound 40 was obtained.  
 
 
 
Scheme 8: Backbone synthesis: a) Benzyl bromide, K2CO3, DMF, 83%; b) 50% TFA, DCM, 0qC, 
100%; c) Triphosgene, NaHCO3, N-methylpiperazine, DCM, 0qC 70%; d) H2, Pd/C, DCM, 100%. 
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3 Conclusions and future work: 
 
To conclude, an efficient and reproducible synthesis towards thiosulfonates for 
incorporating into cysteine protease inhibitors. In an attempt to improve upon this, 
work was undertaken to develop a one pot aliphatic thiosulfonate synthesis method 
which proved unsuccessful. Thus, future work to expand the substrate scope of the 
aliphatic thiosulfonates will focus on the previously validated step-wise approach.  
A new synthesis towards further substituted thiosulfonates, expected to enhance 
stability and potency of the novel warhead, has been initiated. The key methyl non-
natural amino acid derived building block was isolated. This synthesis will also be 
applied starting from D-allo-threonine which will reverse the stereochemistry of the 
key methyl substituent in order to determine if this has any effect on final inhibitors.  
Future work will introduce the thiosulfonate moiety into this new building block 
leading towards a new generation of thiosulfonate cysteine protease inhibitors.  
The backbone of these inhibitor constructs has been successfully synthesised and 
future work will couple this with the new warhead moieties for further testing. This 
testing will include stability tests to determine the effect of both aliphatic substituents 
and further substituted methyl warhead on stability. Enzymatic testing will be carried 
out to correlate these results with the observed potency of the compounds and finally 
application to parasitic infected models will be performed.  
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4 Experimental: 
 
Materials:  
 
All reagents and starting materials were obtained from either Sigma-Aldrich® or 
Fluorochem Ltd. and of the highest available quality, utilized without further 
purification, unless specified otherwise.  
All solvents were obtained from Fisher Scientific. Where necessary (under strict 
anhydrous conditions) solvents were obtained from a dry, distilled source. All 
deuterated solvents were obtained from Cambridge Isotope Laboratories, Inc. 
Solvents were evaporated under reduced pressure at 40°C. Reactions in solution 
were monitored by LCMS. Liquid chromatography mass spectrometry (LCMS) was 
carried out on a Thermo Scientific LCQ Fleet quadrupole mass spectrometer with a 
Dionex Ultimate 3000 LC using a Dr. Maisch Reprosil Gold 120 C18 column (110 Å, 
3 μm, 150×4.0 mm). 1H NMR data was acquired on a Bruker 400 MHz spectrometer 
in MeOD/CDCl3 as solvent. Chemical shifts (δ) are reported in parts per million 
(ppm) relative to the solvent residual signal, MeOD (4.87 ppm)/CDCl3(7.26 ppm). 13C 
NMR data was acquired on a Bruker 400 MHz spectrometer at 101 MHz in 
CDCl3/MeOD as solvent. Chemical shifts (δ) are reported in ppm relative to the 
solvent residual signal, MeOD (49.00 ppm). All automated column chromatography 
purifications were conducted with the Biotage® Isolera One® automated 
chromatograph. Products were purified on Biotage® SNAP Ultra cartridges pre-
packed with Biotage® HP-sphereTMSpherical silica and the gradient determined by 
TLC plate Rf value measurement input. UV absorption was detected with Biotage® 
IsoleraTMSpektra UV detector at both UV1 (254 nm) and UV2 (280 nm) to identify 
fractions for collection. 
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Boc-homophenylalanine (2): Homophenylalanine (25 mmol, 4.48 g, 1 eq) was 
dissolved in 250 mL THF and Boc2O (30 mmol, 6.54 g, 1.2 eq) was added followed 
by NaOH (25 mmol, 0.99 g, 1 eq). H2O was added to the mixture to aid the solvation 
of NaOH. The reaction was allowed to stir overnight, and completion was confirmed 
by TLC (10% EtOAc/ Pet Et). Solution was concentrated in vacuo, taken up in 
EtOAc, the aqueous layer was acidified to pH 4 using citric acid and washed with 
EtOAc (3x), Brine (1x) and dried over MgSO4.  The product was obtained as a 
colourless oil in a 97% yield. Characterization is in accordance with literature. 22  
1H NMR (400 MHz, Chloroform-d) δ 7.47 – 7.04 (m, 5H), 5.15 (d, J = 8.4 Hz, 1H), 
4.38 (m, 1H), 2.72 (m, 2H), 2.20 (m, 1H), 2.03 – 1.87 (m, 1H), 1.44 (s, 9H). 
 
13C NMR (101 MHz, CDCl3) δ 128.48, 128.43, 126.15, 125.81, 60.53, 53.21, 34.13, 
31.64, 28.32, 28.23, 27.42. 
 
 
Methyl ester (3) : Compound 2 was dissolved in 250 mL DMF and MeI was added 
(67 mmol, 4.17 mL, 3 eq) followed by K2CO3 (67 mmol, 9.25 g, 3 eq). The reaction 
was allowed to stir for 5 hours. The solution was then concentrated in vacuo, taken 
up in EtOAc, the aqueous layer back extracted with EtOAc and the combined 
organics were washed with KHSO4 (3x), water (1x), brine (1x) and dried over 
MgSO4. The product was obtained as a colourless oil in a 95% yield. 
Characterization is in accordance with literature. 23 
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1H NMR (400 MHz, Chloroform-d) δ 7.38 – 7.01 (m, 5H), 5.08 (d, J = 8.5 Hz, 1H), 
4.36 (d, J = 7.6 Hz, 1H), 3.71 (s, 3H), 2.67 (t, J = 9.4 Hz, 2H), 2.24 – 1.81 (m, 2H), 
1.45 (s, 9H). 
 
13C NMR (101 MHz, CDCl3) δ 129.14, 128.68, 128.47, 128.39, 126.14, 53.25, 52.25, 
34.37, 31.64, 28.33, 28.24, 28.04. 
 
LC-MS: RT (min): 6.93 (ESI-MS (m/z): 293.50 [M+H]+. 
 
 
 
Alcohol (4): Compound 3 was dissolved in 105 mL EtOH and LiCl (65 mmol, 2.80 g, 
2.5 eq) was added followed by 75 mL of THF (3 mL/mmol). Finally, NaBH4 (65 mmol, 
2.48 g, 2.5 eq) was added and the reaction was allowed to stir overnight and 
followed by TLC. The solution was then quenched with NH4Cl and diluted with 
EtOAc. The aqueous was back extracted with EtOAc (3x), washed with brine (1x) 
and dried over MgSO4. Product was obtained as a yellow oil in a 70% yield. 
Characterization is in accordance with literature. 24 
1H NMR (400 MHz, Chloroform-d) δ 7.18–7.30 (5H, m), 4.64 (1H, s), 3.56–3.71 (2H, 
m), 2.65–2.73 (2H, m), 2.22 (1H, s), 1.74–1.86 (2H, m),1.82 (1H, m), 1.45 (9H, s). 
 
13C NMR (101 MHz, CDCl3) δ 128.51, 128.48, 128.33, 126.02, 125.91, 66.02, 52.60, 
33.28, 32.40, 28.82, 28.39, 28.24. 
 
LC-MS: RT (min): 6.31 (ESI-MS (m/z): 265.67 [M+H]+. 
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Mesylate (5): Alcohol 4 was dissolved in 150 mL DCM and Triethylamine (20 mmol, 
2.83 mL, 5 eq) was added dropwise and the reaction was allowed to stir for 15 mins. 
Methylsulfonate chloride (15 mmol, 0.93 g, 3 eq) was added and the reaction was 
stirred for 1 hour and followed by TLC (50% EtOAc/Pet Et). Upon completion, the 
solution was concentrated in vacuo, taken up in EtOAc, washed with KHSO4 (3x), 
the aqueous was back extracted with DCM (3x), combined organics were washed 
with brine (1x) and dried over MgSO4. The product was obtained as a colorless oil in 
a 75% yield.  
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 6.99 (m, 5H), 4.81 – 4.50 (m, 1H), 4.21 
(d, 7.5 Hz,  2H), 3.87 (s, 1H), 3.00 (s, 3H), 2.86 – 2.58 (m, 2H), 1.87 (m, 2H), 1.46 (s, 
9H). 
 
13C NMR (101 MHz, CDCl3) δ 128.57, 128.43, 128.37, 126.22, 126.18, 71.13, 37.34, 
33.00, 32.09, 28.48, 28.35, 28.14. 
 
 
Thioacetate (6): Cs2CO3 (10 mmol, 3 g, 1eq) was dissolved in 100 mL DMF and 
Thioacetic acid (20 mmol, 1.32 mL, 2eq) was added under N2 atmosphere and 
allowed to stir for 10 minutes. Mesylate 5 was dissolved in minimal amount of DMF 
and added to the mixture. The flask was covered in aluminum foil and the reaction 
was stirred for 3 hours.  Upon completion, the solution was concentrated in vacuo, 
taken in up EtOAc, washed with water (3x), brine (1x) and dried over MgSO4. 
Purification by column chromatography (0 -> 10% EtOAc/Pet Et) yielded the desired 
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product as a dark red oil in a 38% yield. Characterization is in accordance with 
literature. 25 
 
1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.01 (m, 5H), 4.53 (d, 1H), 3.80 (br s, 
1H), 3.21–3.01 (m, 2H), 2.75–2.60 (m, 2H), 2.35 (s, 3H), 1.87–1.74 (m, 2H), 1.45 (s, 
9H);  
 
13C NMR (101 MHz, CDCl3) δ 128.44, 128.36, 128.25, 125.98, 125.70, 36.45, 36.19, 
33.94, 32.36, 30.58, 28.78, 28.38, 28.00. 
 
 
 
Thiol (7): Thioacetate 6 was dissolved in dry THF and the solution was cooled down 
to 0 C. LiAlH4 (1.2 mmol, 1.28 mL, 2 eq) was added dropwise under N2 atmosphere 
and the reaction was followed by TLC. Upon completion, the solution was quenched 
with water and the solvent was evaporated to about half the volume. The solution 
was then diluted in EtOAc, washed with KHSO4 (3x), the aqueous was back 
extracted with EtOAc (2x), the combined organics were washed with brine (1x) and 
dried over MgSO4. The product was obtained as a brown oil in a 92% yield.  
1H NMR (400 MHz, Chloroform-d) δ 7.23 (d, J = 26.1 Hz, 0H), 4.67 (d, J = 8.6 Hz, 
1H), 3.83 (dt, J = 32.3 Hz, 1H), 2.71 – 2.54 (m, 2H), 2.89 – 2.67 (m, 2H), 2.09 (s, 
1H), 1.96 – 1.68 (m, 2H), 1.46 (s, 9H). 
 
13C NMR (101 MHz, CDCl3) δ 128.48, 128.43, 128.35, 126.04, 125.97, 51.20, 34.95, 
32.39, 29.76, 28.47, 28.40, 28.35. 
 
LC-MS: RT (min): 7.15 (ESI-MS (m/z): 243.00 [M+H]+. 
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Cyclohexane warhead (8): Thiol 7 was dissolved in 15 mL DCM and the solution 
was cooled to 0qC. Cyclohexane sulfonyl bromide was added dropwise and the 
solution was removed from ice and allowed to stir at room temperature for 30 
minutes. Reaction was followed via TLC (30% EtOAc/Pet Et). Upon completion, the 
solution was washed 3x KHSO4, the organic layers were collected, dried over 
MgSO4 and concentrated in vacuo. The product was obtained as a yellow oil in a 
20% yield. 
 
1H NMR (400 MHz, Chloroform-d) δ 7.31 – 7.25 (m, 2H), 7.22 – 7.15 (m, 3H), 4.68 
(d, J = 8.8 Hz, 1H), 3.90 – 3.82 (m, 1H), 3.39 (dd, J = 13.4, 4.1 Hz, 1H), 3.18 (dd, J = 
13.8, 7.0 Hz, 1H), 3.17 – 3.11 (m, 1H), 2.68 (dtd, J = 16.2, 13.9, 7.4 Hz, 2H), 2.31 – 
2.22 (m, 2H), 1.91 (ddt, J = 11.5, 4.7, 2.2 Hz, 2H), 1.87 – 1.76 (m, 2H), 1.75 – 1.67 
(m, 1H), 1.63 – 1.49 (m, 2H), 1.46 (s, 9H), 1.37 – 1.26 (m, 2H), 1.26 – 1.15 (m, 1H). 
 
13C NMR (101 MHz, CDCl3) δ 155.36, 140.96, 128.53, 128.38, 126.14, 79.76, 71.37, 
50.06, 41.17, 35.88, 32.26, 28.38, 26.36, 26.21, 25.17, 25.11, 25.04. 
   
LC-MS: RT (min): 5.64 (ESI-MS (m/z): 428.61 [M+H]+. 
 
 
Thr-OMe (25) : D-Threonine (25 mmol, 2.97 g, 1 eq) was dissolved in 150 mL MeOH 
and the solution was cooled to 0 C. Thionyl Chloride (100 mmol, 7.26 mL, 4 eq) was 
added dropwise and the reaction was allowed to stir for 1 hour at 0 C and overnight 
at 70ºC under reflux. Upon completion, the solution was concentrated in vacuo and 
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the methylated product was obtained in a 95% yield. Characterization is in 
accordance with literature. 26 
1H NMR (400 MHz, Methanol-d4) δ 4.30 (dd, J = 6.6, 4.2 Hz, 1H), 3.97 (d, J = 4.1 Hz, 
1H), 3.87 (s, 3H), 1.35 (d, J = 6.6 Hz, 3H). 
 
13C NMR (101 MHz, MeOD) δ 64.98, 58.43, 52.33, 19.14. 
 
[α]D = + 5.76o 
 
IR: 2839, 1743, 1583, 1504 cm-1. 
 
 
Boc-Thr-OMe (26) : Compound 25 was dissolved in 250 mL THF and Boc2O (36 
mmol, 7.85 g, 1.2 eq) was added followed by the dropwise addition of DiPEA (90 
mmol, 15.6 mL, 3 eq). The mixture was stirred overnight at room temperature and 
followed by TLC (15% EtOAc/ Pet Et). Upon completion, the solution was acidified to 
pH 3 using KHSO4, washed with EtOAc (3x) and dried over MgSO4. Product was 
obtained as a colorless oil in an 85% yield. Characterization is in accordance with 
literature. 27 
1H NMR (400 MHz, Chloroform-d) δ 5.47 (d, J = 9.2 Hz, 1H), 4.31 (q, J = 6.6 Hz, 
2H), 3.77 (s, 3H), 2.88 (d, J = 5.4 Hz, 1H), 1.46 (s, 9H), 1.25 (d, J = 6.4 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 67.90, 58.80, 52.37, 28.24, 27.79, 27.34, 19.85. 
 
LC-MS: RT (min): 5.22 (ESI-MS (m/z): 233.58 [M+H]+. 
 
[α]D = + 29.22o 
 
IR: 3425, 2979, 1747, 1693, 1504 cm-1. 
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Boc-Thr-OTBDMS (27) : Compound 26 was dissolved in 150 mL of DMF and 
Imidazole (87.6 mmol, 6.02 g, 3 eq) was added followed by tert-Butyldimethylsilyl 
chloride (35 mmol, 5.27 g, 1.2 eq). The reaction was allowed to stir for 1.5 hours and 
was followed by TLC (10% EtOAc/Pet Et). Upon completion, the mixture was 
washed with diethyl ether (3x), brine (1x) and dried over MgSO4. Purification by 
column chromatography (0 -> 5% EtOAc/Pet Et) yielded compound 18 in a 25% 
yield.  
1H NMR (400 MHz, Methanol-d4) δ 4.35 (dd, J = 6.3, 2.5 Hz, 1H), 4.07 (d, J = 2.4 Hz, 
1H), 3.65 (s, 3H), 1.39 (s, 9H), 1.12 (d, J = 6.3 Hz, 3H), 0.79 (s, 9H), 0.02 (s, 3H), -
0.05 (s, 3H). 
 
13C NMR (101 MHz, MeOD) δ 68.74, 59.47, 51.35, 27.69, 27.56, 27.31, 25.25, 
24.88, 24.85, 19.77, -5.54, -6.41. 
 
LC-MS: RT (min): 8.09 (ESI-MS (m/z): 347.58 [M+H]+. 
 
[α]D = + 3.34o 
 
IR: 2929, 2856, 1754, 1716, 1495, 1391. 
 
 
 
 
Alcohol (28) : Compound 27 was dissolved in dry tetrahydrofuran (THF) and the 
solution was cooled down to -78 C using dry ice/acetone. Lithium aluminium hydride 
(LiAlH4 1.0M in THF) was added dropwise under N2 atmosphere and the solution 
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was allowed to stir for 1 hour and was followed by TLC (20% EtOAc/ Pet Et). 
Reaction completion was confirmed by LCMS and the product was obtained as a 
colourless oil in quantitative yield.  
1H NMR (400 MHz, Methanol-d4) δ 4.11 – 3.99 (m, 1H), 3.97 – 3.85 (m, 1H), 3.53 – 
3.44 (m, 2H), 1.40 (s, 9H), 1.09 (d, J = 8.3 Hz, 3H), 0.90 – 0.83 (m, 1H), 0.05 (s, 3H), 
0.03 (s, 3H). 
 
13C NMR (101 MHz, MeOD) δ 65.81, 61.68, 56.92, 27.85, 27.44, 27.23, 25.13, 
25.06, 24.91, 18.98, -4.86, -6.03. 
 
LC-MS: RT (min): 7.67 (ESI-MS (m/z): 319.67 [M+H]+. 
 
 
Alkene (30): Oxalyl Chloride (2.5 eq, 3.75 mmol) was dissolved in 25 mL dry DCM, 
cooled down to -78ºC and dry DMSO (5 eq, 7.5 mmol) was added dropwise. The 
solution was allowed to stir for 30 minutes, after which alcohol 19 (1 eq, 1.5 mmol) 
was added dropwise and allowed to stir for 45 minutes before adding NEt3. The 
reaction was followed by TLC (20% EtOAc) and LCMS. Upon completion, the 
solution was diluted with DCM, washed with 1M HCl (1x), NaHCO3 (1x), H2O (1x) 
and dried over MgSO4. The aldehyde was concentrated in vacuo and used directly 
for the Wittig reaction. The triphenylphosphine ylide was dissolved in dry THF, 
cooled to 0ºC, NaH (60% mineral oil, 1.2 eq, 5.1 mmol) was added and stirred for 1 
hour.  The freshly made aldehyde was dissolved in THF and added dropwise to the 
solution. Reaction was followed via TLC (20% EtOAc) and LCMS. Upon completion, 
the product was washed with 1M HCl (1x), Brine (1x), dried over MgSO4. The 
product was obtained as a dark orange solid.  
 
LC-MS: RT (min): 8.10 (ESI-MS (m/z): 392.63 [M+H]+. 
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Boc-Phe-OBn (37) : Boc protected amino acid 36 was dissolved 250 mL DMF and 
Benzyl bromide (24 mmol, 2.85 mL, 1.5 eq) was added, followed by K2CO3 (64 
mmol, 8.84 g, 4 eq) and allowed to stir overnight. The reaction was followed by TLC 
(15% EtOAc/Pet Et) and concentrated in vacuo, taken up in EtOAc, washed with 
water (2x), back extracted with EtOAc and dried over MgSO4. Product was obtained 
as colourless oil in an 83% yield. Characterization is in accordance with literature. 28 
1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.19 (m, 10H), 5.16 – 5.07 (m, 2H), 4.98 
(d, J = 8.5 Hz, 1H), 4.67 – 4.54 (m, 1H), 3.07 (m, 2H), 1.41 (s, 9H). 
 
13C NMR (101 MHz, CDCl3) δ 129.52, 129.48, 129.41, 129.36, 128.66, 128.59, 
128.27, 127.63, 126.98, 126.29, 67.11, 54.46, 38.28, 28.62, 28.31, 28.25. 
 
 
MPip-Phe-OBn (39): Compound 38 was dissolved in 100 mL DCM and 100 mL 
NaHCO3 were added followed by Triphosgene (6.64 mmol, 2.10 mL, 0.5 eq). The 
reaction was allowed to stir for 1 hour and was followed by TLC (20% EtOAc/Pet Et).  
1-Methylpiperazine was added dropwise and the solution was allowed to stir 
overnight. Once the reaction was completed, the aqueous layer was back extracted 
with DCM and the combined organics were washed with Brine (1x) and dried over 
MgSO4. Purification by column chromatography (0 -> 5% MeOH/DCM) yielded the 
product as a yellow oil in a 70% yield. Characterization is in accordance with 
literature. 29 
1H NMR (400 MHz, Chloroform-d) δ 7.57 – 6.82 (m, 10H), 5.23 – 5.05 (m, 2H), 4.85 
(s, 2H), 3.36 (d, J = 5.1 Hz, 4H),3.10 (m,2H) 2.38 (d, J = 5.2 Hz, 4H), 2.31 (s, 3H). 
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LC-MS: RT (min): 5.39 (ESI-MS (m/z): 381.92 [M+H]+. 
 
 
MPip-Phe-OH (40) : Compound 39 was dissolved in EtOH/AcOH (1%) and Pd/C 
was added under a H2 atmosphere. The reaction was allowed to stir for 3 hours and 
the product was obtained in a quantitive yield. Characterization is in accordance with 
literature. 30 
1H NMR (400 MHz, Chloroform-d) δ 7.34 – 7.11 (m, 5H), 4.56 (m, 1H), 3.74 – 3.36 
(m, 4H), 3.09 (d, J = 7.4 Hz, 2H), 2.73 (s, 4H), 2.51 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 129.63, 128.13, 127.11, 126.48, 126.43, 55.74, 55.23, 
53.20, 44.86, 44.06, 8.59. 
 
LC-MS: RT (min): 4.39 (ESI-MS (m/z): 291.83 [M+H]+. 
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